JP4392163B2 - 肺癌用遺伝子マーカー - Google Patents
肺癌用遺伝子マーカー Download PDFInfo
- Publication number
- JP4392163B2 JP4392163B2 JP2002504687A JP2002504687A JP4392163B2 JP 4392163 B2 JP4392163 B2 JP 4392163B2 JP 2002504687 A JP2002504687 A JP 2002504687A JP 2002504687 A JP2002504687 A JP 2002504687A JP 4392163 B2 JP4392163 B2 JP 4392163B2
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- blood
- markers
- pcr
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims description 61
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 60
- 201000005202 lung cancer Diseases 0.000 title claims description 60
- 239000003550 marker Substances 0.000 title claims description 35
- 230000002068 genetic effect Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 56
- 210000004369 blood Anatomy 0.000 claims description 53
- 239000008280 blood Substances 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 108010066302 Keratin-19 Proteins 0.000 claims description 16
- 108090000058 Syndecan-1 Proteins 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 15
- 102000008186 Collagen Human genes 0.000 claims description 13
- 229920001436 collagen Polymers 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 210000004879 pulmonary tissue Anatomy 0.000 claims description 3
- 102000018317 Keratin-19 Human genes 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 61
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 40
- 206010028980 Neoplasm Diseases 0.000 description 31
- 238000010240 RT-PCR analysis Methods 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 17
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 102000003705 Syndecan-1 Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 210000005265 lung cell Anatomy 0.000 description 8
- 230000001351 cycling effect Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 108091060211 Expressed sequence tag Proteins 0.000 description 5
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 208000013210 hematogenous Diseases 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000018329 Keratin-18 Human genes 0.000 description 3
- 108010066327 Keratin-18 Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WZIMSXIXZTUBSO-UHFFFAOYSA-N 2-[[bis(carboxymethyl)amino]methyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CN(CC(O)=O)CC(O)=O WZIMSXIXZTUBSO-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 238000004450 analytical method by type Methods 0.000 description 1
- 230000000417 anti-transforming effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000010033 lipoblastoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21572700P | 2000-06-21 | 2000-06-21 | |
| US24397600P | 2000-10-27 | 2000-10-27 | |
| PCT/US2001/019980 WO2001098539A2 (en) | 2000-06-21 | 2001-06-21 | Gene markers for lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500895A JP2004500895A (ja) | 2004-01-15 |
| JP2004500895A5 JP2004500895A5 (enExample) | 2006-05-18 |
| JP4392163B2 true JP4392163B2 (ja) | 2009-12-24 |
Family
ID=26910326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504687A Expired - Fee Related JP4392163B2 (ja) | 2000-06-21 | 2001-06-21 | 肺癌用遺伝子マーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7214781B2 (enExample) |
| EP (1) | EP1356093A2 (enExample) |
| JP (1) | JP4392163B2 (enExample) |
| CN (1) | CN1471587A (enExample) |
| AU (1) | AU2001270082A1 (enExample) |
| WO (1) | WO2001098539A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011111820A1 (ja) * | 2010-03-11 | 2011-09-15 | 株式会社インテックシステム研究所 | 肺癌または子宮頸癌の診断マーカー |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158293A0 (en) | 2001-04-10 | 2004-05-12 | Agensys Inc | Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same |
| EP1510587B1 (en) * | 2002-05-21 | 2011-07-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
| GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| US20050186215A1 (en) * | 2004-02-04 | 2005-08-25 | Kwok Tim T. | CUDR as biomarker for cancer progression and therapeutic response |
| JP2009504168A (ja) | 2005-08-17 | 2009-02-05 | メディクシス エス.エー. | Ck19発現を確認する組成物及び方法 |
| WO2007092105A1 (en) * | 2006-02-03 | 2007-08-16 | Hill's Pet Nutrition, Inc. | Method for evaluating kidney function in a feline by measuring ghrelin hormone levels |
| WO2007130967A2 (en) * | 2006-05-01 | 2007-11-15 | Siemens Healthcare Diagnostics Inc. | Novel oligonucleotide primers and methods for dna replication |
| KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
| WO2009043115A1 (en) * | 2007-10-04 | 2009-04-09 | Fermiscan Australia Pty Limited | Method for identifying biomarkers which are diagnostic for a pathological condition |
| WO2012031374A1 (zh) * | 2010-09-09 | 2012-03-15 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| ES2705237T3 (es) | 2012-06-06 | 2019-03-22 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón |
| MY205689A (en) | 2017-10-02 | 2024-11-06 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| WO2020007898A1 (en) * | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
| US12338291B2 (en) * | 2019-06-17 | 2025-06-24 | Visterra, Inc. | Humanized antibody molecules to CD138 and uses thereof |
| KR20210020417A (ko) * | 2019-08-14 | 2021-02-24 | 연세대학교 산학협력단 | 메티오닐-티알엔에이 합성효소 및 판사이토케라틴을 이용한 폐암 진단 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272057A (en) * | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| ATE345387T1 (de) | 1998-03-18 | 2006-12-15 | Corixa Corp | Verbindungen und verfahren für therapie und diagnose von lungenkrebs |
-
2001
- 2001-06-21 WO PCT/US2001/019980 patent/WO2001098539A2/en not_active Ceased
- 2001-06-21 US US10/297,277 patent/US7214781B2/en not_active Expired - Fee Related
- 2001-06-21 JP JP2002504687A patent/JP4392163B2/ja not_active Expired - Fee Related
- 2001-06-21 CN CNA018115438A patent/CN1471587A/zh active Pending
- 2001-06-21 AU AU2001270082A patent/AU2001270082A1/en not_active Abandoned
- 2001-06-21 EP EP01948623A patent/EP1356093A2/en not_active Withdrawn
-
2005
- 2005-10-19 US US11/255,001 patent/US20060275783A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011111820A1 (ja) * | 2010-03-11 | 2011-09-15 | 株式会社インテックシステム研究所 | 肺癌または子宮頸癌の診断マーカー |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001098539A2 (en) | 2001-12-27 |
| US7214781B2 (en) | 2007-05-08 |
| WO2001098539A3 (en) | 2003-08-14 |
| CN1471587A (zh) | 2004-01-28 |
| EP1356093A2 (en) | 2003-10-29 |
| US20060275783A1 (en) | 2006-12-07 |
| US20030215828A1 (en) | 2003-11-20 |
| JP2004500895A (ja) | 2004-01-15 |
| AU2001270082A1 (en) | 2002-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4392163B2 (ja) | 肺癌用遺伝子マーカー | |
| US6960433B1 (en) | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer | |
| JP3422776B2 (ja) | 乳癌を診断、監視、病期決定、造影及び治療する新規な方法 | |
| JP2002523760A (ja) | 様々な癌を診断、監視、段階づけ、造影及び治療する新規な方法 | |
| EP0284362A2 (en) | Molecular markers | |
| WO2012019300A1 (en) | Endometrial cancer biomarkers and methods of identifying and using same | |
| JP2002527758A (ja) | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 | |
| JP2002541805A (ja) | 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法 | |
| JP2002525031A (ja) | 大腸癌の診断、監視、病期決定、画像処理及び治療の新規方法 | |
| WO2009066820A1 (en) | Characterization of cxcl-16 as a tumor associated marker of colorectal cancer | |
| CN106701902B (zh) | Foxr2基因和表达产物在肝癌诊断与治疗中的应用 | |
| JP2002527757A (ja) | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 | |
| JPH08500731A (ja) | 診断法 | |
| KR102560020B1 (ko) | 암의 진단용 조성물 | |
| WO2009066821A1 (en) | Characterization of esm-1 as a tumor associated marker of colorectal cancer | |
| CN103937871A (zh) | Srrp35基因和表达产物在癌症诊断与治疗中的应用 | |
| KR101128640B1 (ko) | 간암 진단용 마커로서의 rps 14의 용도 | |
| KR100861465B1 (ko) | 위암 유발 유전자 ZNF312b와 이에 의해 코드되는단백질 및 이를 이용한 위암 진단 키트 | |
| JP2002526760A (ja) | 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法 | |
| KR100894511B1 (ko) | 만성골수성백혈병 진단용 다중(multiplex)RT-PCR용 프라이머, 이 프라이머를 포함하는 진단조성물 및 키트 | |
| JP2004321102A (ja) | 胃癌由来の転移癌細胞の検出方法 | |
| KR20070027659A (ko) | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 | |
| JP3524536B2 (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 | |
| Kekeeva et al. | Analysis of SYT/SSX1 and SYT/SSX2 fusion genes in synovial sarcoma | |
| JP2004159600A (ja) | 癌の診断方法及び癌の診断用キット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060322 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060322 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090820 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090929 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091009 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121016 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4392163 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131016 Year of fee payment: 4 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131016 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |